The clinical utility of tuberculin skin tests: a single-center experience Utilidad clínica de la prueba cutánea de tuberculina: una experiencia en un centro hospitalario

Creative Commons License

ÜZER F., ÖNER Ş., Gokmen Y., Yeşil Ö., ÖZDEMİR T.

Colombia Medica, vol.53, no.3, 2022 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 53 Issue: 3
  • Publication Date: 2022
  • Doi Number: 10.25100/cm.v53i3.5055
  • Journal Name: Colombia Medica
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE
  • Keywords: Immunosuppression Therapy, Interferon-gamma Release Tests, Tuberculin test, Tuberculosis
  • Akdeniz University Affiliated: Yes


© 2022.Background: Tuberculin skin test (TST) has played an essential in the diagnosis of latent tuberculosis infection (LTBI) for nearly a century. Objective: This study aimed to investigate the general characteristics of patients tested with TST in a tertiary hospital within two years. Methods: All patients who were evaluated to screen for tuberculosis and received a TST were included. The Mantoux method was used for TST administration. Results: A total of 661 patients, 345 (52.2%) men and 316 (47.8%) women, with a mean age of 43.0 ±15.9 years, were included in the study. Accordingly, TST was performed prior to anti-TNF biological agent therapy for 50% (331) of the participants, for LTBI screening before solid organ and/or hematological stem cell transplantation for 20.4% (135), for screening following contact with tuberculosis for 25.1% (166), for screening of healthcare professionals for 1.1% (7), and medical report for 3.3% (22). 2.7% of the patients who took TST were diagnosed with active tuberculosis (14 with pulmonary tuberculosis and 4 with extrapulmonary tuberculosis). QuantiFERON-TB Gold (QFT) test was performed in 332 (50.2%) patients with anergic TST results. According to TST and QFT test results, 28.3% (187) of the patients were started on tuberculosis prophylaxis. Conclusion: While TST is most performed for LTBI screening prior to biological agent therapy, almost one-fourth of patients taking TST require tuberculosis prophylaxis. On the other hand, about half of the patients require an additional QFT test.